David Cameron reveals prostate cancer diagnosis | UK | News
David Cameron announced that he was diagnosed with prostate cancer. The former British Prime Minister announced that he became aware of the disease after his wife Samantha urged him to get tested in 2022.
The 59-year-old told Times He said he and his wife, Samantha, listened to an interview with Nick Jones, founder of the Soho House group, in which Jones talked about getting a prostate-specific antigen (PSA) test in 2022. Inspired by this discussion, Samantha stressed the importance of proactive conversations about health and early detection, urging Cameron to discuss the issue with his GP during a routine health check.
He said: “You always hope for the best. You have an MRI scan with a few black dots on it. You think, ‘Oh, that’s probably okay’.”
“But when the biopsy results come back and say you have prostate cancer, you are always afraid to hear those words.
“And then it’s literally coming out of the doctor’s mouth and you think, ‘Oh, no, he’s going to say it. He’s going to say it. Oh my God, he said it.'”
The former Conservative leader stressed that encouraging men to undergo prostate specific antigen (PSA) testing could be a life-saving step. Such proactive health measures have the potential to prevent countless deaths among the approximately 12,000 men in the UK who die each year from prostate cancer, the country’s deadliest male cancer, he said.
She told The Times: “I would feel bad if I didn’t come forward and say I had this experience. I had a scan. It helped me discover something was wrong. It gave me a chance to deal with it.”
Prostate cancer is most common in men over 50 or of Black African or Caribbean descent, according to the NHS. Anyone with a prostate can get it.
Initially, there are usually no signs or symptoms. Later symptoms may include back, hip, or pelvic pain or difficulty maintaining an erection. You may also have trouble urinating, but this could be a sign of other prostate problems.
The former Prime Minister voiced his strong support for the renewed campaign to introduce prostate cancer screening for men considered most at risk, stressing that scientific advances now provide a clear rationale for such measures.
Speaking to The Times, Cameron argued that the new technology had significantly improved the accuracy and effectiveness of early tests, changing the calculations around its benefits. He believes this progress highlights the need for a national screening program that is not only compelling but urgent, with the potential to save thousands of lives through early diagnosis and treatment.
